Show simple item record

dc.contributor.authorAl-Adra, DPen
dc.contributor.authorGill, RSen
dc.contributor.authorAxford, SJen
dc.contributor.authorShi, Xen
dc.contributor.authorKneteman, Nen
dc.contributor.authorLiau, Siong-Sengen
dc.date.accessioned2015-04-13T14:55:21Z
dc.date.available2015-04-13T14:55:21Z
dc.date.issued2014-10-07en
dc.identifier.citationEuropean Journal of Surgical Oncology (EJSO) Volume 41, Issue 1, January 2015, Pages 120–127. DOI: 10.1016/j.ejso.2014.09.007en
dc.identifier.issn0748-7983
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/247307
dc.description.abstractRadioembolization with yttrium-90 microspheres offers an alternative treatment option for patients with unresectable intrahepatic cholangiocarcinoma (ICC). However, the rarity and heterogeneity of ICC makes it difficult to draw firm conclusions about treatment efficacy. Therefore, the goal of the current study is to systematically review the existing literature surrounding treatment of unresectable ICCs with yttrium-90 microspheres and provide a comprehensive review of the current experience and clinical outcome of this treatment modality. We performed a comprehensive search of electronic databases for ICC treatment and identified 12 studies with relevant data regarding radioembolization therapy with yttrium-90 microspheres. Based on pooled analysis, the overall weighted median survival was 15.5 months. Tumour response based on radiological studies demonstrated a partial response in 28% and stable disease in 54% of patients at three months. Seven patients were able to be downstaged to surgical resection. The complication profile of radioembolization is similar to that of other intra-arterial treatment modalities. Overall survival of patients with ICC after treatment with yttrium-90 microspheres is higher than historical survival rates and shows similar survival to those patients treated with systemic chemotherapy and/or trans-arterial chemoembolization therapy. Therefore, the use of yttrium-90 microspheres should be considered in the list of available treatment options for ICC. However, future randomized trials comparing systemic chemotherapy, TACE and local radiation will be required to identify the optimal treatment modality for unresectable ICC.
dc.description.sponsorshipS-S Liau is in receipt of the MRC Clinician Scientist Fellowship. He is also funded by University of Cambridge Parke-Davis Fellowship, Royal Society of Medicine Ellison-Cliffe Fellowship, Dowager Countess Eleanor Peel Fellowship, HCA International Foundation Fellowship, European Society of Surgical Oncology Minor Fellowship, and MRC Centenary Early Career Award.
dc.languageEnglishen
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution 2.0 UK: England & Wales*
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/uk/*
dc.subjectCholangiocarcinomaen
dc.subjectRadioembolizationen
dc.subjectYttrium-90 microsphereen
dc.titleTreatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: A systematic review and pooled analysisen
dc.typeArticle
dc.description.versionThis is the final published version. It first appeared at http://www.sciencedirect.com/science/article/pii/S074879831401097X#.en
prism.endingPage127
prism.publicationDate2014en
prism.publicationNameEuropean Journal of Surgical Oncologyen
prism.startingPage120
prism.volume41en
dc.rioxxterms.funderMRC
dcterms.dateAccepted2014-09-22en
rioxxterms.versionofrecord10.1016/j.ejso.2014.09.007en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2014-10-07en
dc.identifier.eissn1532-2157
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idMRC (G1002543)
pubs.funder-project-idMRC (G1002543)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution 2.0 UK: England & Wales